A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is application/pdf
.
Linezolid as a Potentially Effective Drug for the Treatment of Multidrug-Resistant Tuberculosis in Japan
2017
Japanese journal of infectious diseases (Print)
Linezolid (LZD) is classified as a WHO group 5 drug used in the treatment of tuberculosis (TB). Although its efficacy and long-term safety have not yet been established, it is being increasingly used in the treatment of multidrug resistant tuberculosis (MDR-TB) and extensive multidrugresistant tuberculosis (XDR-TB). The current study is a single-center retrospective clinical analysis of hospitalized M/XDR-TB patients in Fukujuji Hospital involving 26 patients (18 men and 8 women) consecutively
doi:10.7883/yoken.jjid.2015.629
pmid:27000461
fatcat:5rfimdvd4nfhhbf4dyvbrzdb2a